HU184631B - Process for preparing cef-3-em-4-carboxylic acid derivatives with antiaiotic activity - Google Patents

Process for preparing cef-3-em-4-carboxylic acid derivatives with antiaiotic activity Download PDF

Info

Publication number
HU184631B
HU184631B HU79GA1287A HUGA001287A HU184631B HU 184631 B HU184631 B HU 184631B HU 79GA1287 A HU79GA1287 A HU 79GA1287A HU GA001287 A HUGA001287 A HU GA001287A HU 184631 B HU184631 B HU 184631B
Authority
HU
Hungary
Prior art keywords
formula
compound
group
acid
cef
Prior art date
Application number
HU79GA1287A
Other languages
English (en)
Hungarian (hu)
Inventor
Cynthia H O'callaghan
David G H Livermore
Christopher E Newall
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of HU184631B publication Critical patent/HU184631B/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C07D501/14—Compounds having a nitrogen atom directly attached in position 7
    • C07D501/16—Compounds having a nitrogen atom directly attached in position 7 with a double bond between positions 2 and 3
    • C07D501/20—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids
    • C07D501/24—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids with hydrocarbon radicals, substituted by hetero atoms or hetero rings, attached in position 3
    • C07D501/38—Methylene radicals, substituted by nitrogen atoms; Lactams thereof with the 2-carboxyl group; Methylene radicals substituted by nitrogen-containing hetero rings attached by the ring nitrogen atom; Quaternary compounds thereof
    • C07D501/46—Methylene radicals, substituted by nitrogen atoms; Lactams thereof with the 2-carboxyl group; Methylene radicals substituted by nitrogen-containing hetero rings attached by the ring nitrogen atom; Quaternary compounds thereof with the 7-amino radical acylated by carboxylic acids containing hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/587—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with aliphatic hydrocarbon radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms, said aliphatic radicals being substituted in the alpha-position to the ring by a hetero atom, e.g. with m >= 0, Z being a singly or a doubly bound hetero atom
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cephalosporin Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HU79GA1287A 1978-05-26 1979-05-25 Process for preparing cef-3-em-4-carboxylic acid derivatives with antiaiotic activity HU184631B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB2291178 1978-05-26

Publications (1)

Publication Number Publication Date
HU184631B true HU184631B (en) 1984-09-28

Family

ID=10187065

Family Applications (1)

Application Number Title Priority Date Filing Date
HU79GA1287A HU184631B (en) 1978-05-26 1979-05-25 Process for preparing cef-3-em-4-carboxylic acid derivatives with antiaiotic activity

Country Status (10)

Country Link
JP (6) JPS54154786A (fr)
KR (2) KR830000606B1 (fr)
AT (2) AT369380B (fr)
BE (1) BE876538A (fr)
CA (1) CA1132538A (fr)
CY (1) CY1168A (fr)
GB (2) GB2058791B (fr)
HU (1) HU184631B (fr)
IT (1) IT1210588B (fr)
ZA (2) ZA792581B (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2457295A1 (fr) * 1979-05-25 1980-12-19 Glaxo Group Ltd Composes intermediaires pour la preparation de cephalosporines
ZA806977B (en) * 1979-11-19 1981-10-28 Fujisawa Pharmaceutical Co 7-acylamino-3-vinylcephalosporanic acid derivatives and processes for the preparation thereof
DE3006888A1 (de) * 1980-02-23 1981-09-10 Hoechst Ag, 6000 Frankfurt Cephalosporinderivate und verfahren zu ihrer herstellung
JPS5756486A (en) * 1980-08-11 1982-04-05 Fujisawa Pharmaceut Co Ltd Novel cephem compound or its salt, their preparation and prophylactic or remedy for microbism containing the same as active ingredient
US4336253A (en) * 1981-03-11 1982-06-22 Eli Lilly And Company Cephalosporin antibiotics
DE3207840A1 (de) * 1982-03-04 1983-09-15 Hoechst Ag, 6230 Frankfurt "cephalosporinderivate und verfahren zu ihrer herstellung"
DE3374410D1 (en) 1982-06-28 1987-12-17 Bristol Myers Co Cephalosporin derivatives, a process for the manufacture thereof and pharmaceutical compositions containing said derivatives
DE3239365A1 (de) * 1982-10-23 1984-04-26 Bayer Ag, 5090 Leverkusen Neue cephalosporine und verfahren zu ihrer herstellung
EP0113568B1 (fr) * 1982-12-27 1990-04-04 Eli Lilly And Company Intermédiaires pour la préparation de ceftazidine, et procédé pour leur préparation
DE3313818A1 (de) * 1983-04-16 1984-10-18 Hoechst Ag, 6230 Frankfurt Neue kristallmodifikation von ceftazidim
GB8413152D0 (en) * 1983-06-03 1984-06-27 Ici Pharma Cephalosporin derivatives
US4855420A (en) * 1983-06-03 1989-08-08 Ici Pharma Cephalosporin derivatives
GB8406218D0 (en) * 1984-03-09 1984-04-11 Glaxo Group Ltd Process
GB8410992D0 (en) * 1984-04-30 1984-06-06 Glaxo Group Ltd Process
GB8410991D0 (en) * 1984-04-30 1984-06-06 Glaxo Group Ltd Process
GB8410993D0 (en) * 1984-04-30 1984-06-06 Glaxo Group Ltd Process
FI851934L (fi) * 1984-05-30 1985-12-01 Ici Plc Kefalosporinderivat.
CA1296012C (fr) 1986-03-19 1992-02-18 Susumu Nakagawa Derives de 6,7-dihydroxy-isoquinaline
KR0164458B1 (ko) * 1995-04-04 1999-01-15 김은영 암모니오세팔로스포린 계열 항생제 및 그의 제조방법
US5872249A (en) * 1995-09-01 1999-02-16 Korea Institute Of Science And Technology 3-ammoniopropenyl cephalosporin compounds as antibacterial agents and process for preparing the same
JPH09110877A (ja) 1995-10-17 1997-04-28 Katayama Seiyakushiyo:Kk セフェム化合物、その製造法及びそれを含有する抗菌剤

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS597717B2 (ja) * 1976-09-08 1984-02-20 武田薬品工業株式会社 セフアロスポリン誘導体およびその製造法

Also Published As

Publication number Publication date
JPS54154786A (en) 1979-12-06
IT8149648A0 (it) 1981-11-06
GB2025398B (en) 1982-08-11
ZA792581B (en) 1981-01-28
GB2025398A (en) 1980-01-23
JPS6322093A (ja) 1988-01-29
BE876538A (fr) 1979-11-26
JPH0257073B2 (fr) 1990-12-03
KR830000835B1 (ko) 1983-04-20
JPH0257069B2 (fr) 1990-12-03
JPS6127921A (ja) 1986-02-07
CA1132538A (fr) 1982-09-28
JPS625916B2 (fr) 1987-02-07
AT369381B (de) 1982-12-27
GB2058791A (en) 1981-04-15
ATA173881A (de) 1982-05-15
ZA807323B (en) 1981-02-25
CY1168A (en) 1983-06-10
JPH0257554B2 (fr) 1990-12-05
KR830000606B1 (ko) 1983-03-17
GB2058791B (en) 1982-11-24
AT369380B (de) 1982-12-27
JPS6127989A (ja) 1986-02-07
ATA173981A (de) 1982-05-15
IT1210588B (it) 1989-09-14
JPS6354689B2 (fr) 1988-10-28
JPS6127990A (ja) 1986-02-07
JPS55149289A (en) 1980-11-20

Similar Documents

Publication Publication Date Title
US4258041A (en) (6R,7R)-7-[(Z)-2-(2-Aminothiazol-4-yl)-2-(2-carboxyprop-2-oxyimino)acetamido]-3-(1-pyridiniummethyl)-ceph-3-em-4-carboxylate and salts thereof
HU184631B (en) Process for preparing cef-3-em-4-carboxylic acid derivatives with antiaiotic activity
US4621081A (en) Cephalosporin antibiotics
US4464368A (en) Cephalosporin antibiotics
US5202315A (en) Cephalosporin compounds
US4315005A (en) Cephalosporin antibiotics
US4427675A (en) Cephalosporin antibiotics
KR830001130B1 (ko) 세팔로스포린 항생제의 제조방법
KR830001891B1 (ko) 세팔로스포린 항생물질의 제조방법
IE49099B1 (en) Cephalosporin compounds
US4560683A (en) Cephalosporin antibiotics
US4179502A (en) 7[2-Hydroxyiminoacetamido]cephalosporins
GB2046261A (en) Cephalosporin antibiotics
KR830001593B1 (ko) 세팔로스포린 항생제의 제조방법
CA1129408A (fr) Cephalosporine
SE438508B (sv) Nya cefalosporinantibiotika samt forfarande for framstellning derav
SE438859B (sv) 7-acylamido-3-karbamoyloximetyl-3-cefem-4-karboxylsyraderivat och forfarande for framstellning derav
EP0095329A2 (fr) Céphalosporines antibiotiques
GB2027692A (en) Cephalosporin Antibiotics
GB2183630A (en) Cephalosporin antibiotics
GB2183629A (en) Cephalosporin antibiotics

Legal Events

Date Code Title Description
HU90 Patent valid on 900628